ArticleDepression and anxiety2026
Connectome Gradient-Based Subtyping of Major Depressive Disorder Reveals Distinct Neurobiological and Transcriptomic Signatures.
Article in Depression and anxiety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Major depressive disorder (MDD) exhibits significant heterogeneity, and identifying these distinct biological subtypes aids clinical intervention. In this study, we employed functional gradient and Hydra clustering methods to distinguish subtypes of depression. Method: Imaging data were derived from a large-scale, multicenter MDD imaging database, comprising 1067 patients with MDD and 907 healthy controls (HCs). Based on the principal functional gradient, the Hydra method was employed to distinguish subtypes of MDD. We employed the Mann-Whitney Results: Using principal functional gradients, we identified two subtypes of MDD. Compared with HCs, subtype 1 exhibited abnormal functional gradient values in the dorsal attention network (DAN), ventral attention network (VAN), limbic network (LIB), frontoparietal network (FTP), and default mode network (DMN); subtype 2 exhibited abnormal functional gradient values in the visual network (VIS), somatosensory network (SMT), DAN, VAN, and DMN. Transcriptomics revealed that subtype 1 functional gradient abnormalities were significantly correlated with theory mind, 5-hydroxytryptamine (5-HT) 1B; subtype 2 functional gradient abnormalities were significantly correlated with motor function, dopamine D2 receptor, and norepinephrine transporter (NET). Conclusions: Our research deepens the understanding of the biological diversity of MDD, providing a biologically grounded framework for stratifying patients, which may inform the future design of hypothesis-driven clinical trials targeting specific cognitive or sensorimotor circuits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.